Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Ionis Pharmaceuticals (NASDAQ:IONS) Executive Vice President, Chief Clinical Development Officer Eugene Schneider, sold 9,549 shares of common stock on August 4, 2025, for approximately $408,701. The stock, which has gained 31% over the past six months and currently trades near $43, appears overvalued according to InvestingPro analysis.
The shares were sold at a weighted average price of $42.8004, in multiple transactions ranging from $42.315 to $43.45. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 2, 2025. Following the transaction, Schneider directly owns 51,507 shares of Ionis Pharmaceuticals. For comprehensive insider trading analysis and additional insights, including 10 key investment tips for IONS, visit InvestingPro.
In other recent news, Ionis Pharmaceuticals reported strong financial results for the second quarter of 2025. The company achieved a revenue of $452 million, significantly exceeding the forecasted $286 million, resulting in a 58.04% revenue surprise. Additionally, earnings per share were reported at $0.70, a notable improvement from the expected -$0.24. Following these results, Ionis Pharmaceuticals raised its financial guidance for the remainder of the year. Morgan Stanley (NYSE:MS) responded to these developments by upgrading the company’s stock rating from Equalweight to Overweight and increasing the price target to $62.00. H.C. Wainwright also raised its price target for Ionis Pharmaceuticals to $65.00, maintaining a Buy rating. Both firms highlighted the successful launch of Ionis’ treatment for familial chylomicronemia syndrome as a positive factor. These recent developments reflect a period of growth and optimism for Ionis Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.